辉瑞54亿美金“打水漂”了

新浪医药
27 Sep 2024

54亿美金“打水漂”,辉瑞扼腕长叹。根据9月25日发布的公告,该巨头自愿撤回目前所有获批用于治疗镰状细胞性贫血(SCD)的OXBRYTA?(voxelotor)批次,并将停止全球所有正在进行的voxelotor临床试验和扩大可及性计划。两年前,辉瑞砸钱买下这款已经成功商业化的产品。但令其始料未及,Oxbryta落得个草草收场。此次决定基于新的临床数据,“现在表明Oxbryta的总体益处不再超过其...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10